Inhibition of the STAT3 pathway has been shown to overcome resistance of lung cancer [212,213], head and neck cancer [214], pancreatic cancer [215], and glioma [216] to anti-EGFR therapy. This evidence concerns the gene STAT3 and central nervous system cancer.